Comparison of Intralesional Hyaluronic Acid vs . Verapamil for the Treatment of Acute Phase Peyronie’s Disease: A Prospective, Open-Label Non-Randomized Clinical Study
| Autor: | Andrea Cocci, Fabrizio Di Maida, Gianmartin Cito, Pierangelo Verrienti, Nicola Laruccia, Riccardo Campi, Andrea Mari, Marina Di Mauro, Marco Falcone, Giovanni E. Cacciamani, Giulio Garaffa, Andrea Minervini, Giorgio Ivan Russo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | The World Journal of Men's Health, Vol 39, Iss 2, Pp 352-357 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2287-4208 2287-4690 |
| DOI: | 10.5534/wjmh.190108 |
| Popis: | Purpose: To compare the efficacy and safety of intralesional hyaluronic acid (HA) as compared with verapamil injection in patients with Peyronie’s disease (PD). Materials and Methods: Between January 2015 and December 2018, men in PD acute phase were prospectively recruited. This open-label, prospective study included 2 different protocols. Group A: 8-week cycle of weekly intraplaque injections with HA; Group B: 8-week cycle of weekly intraplaque injections with verapamil. Penile curvature, plaque size, International Index of Erectile Function (IIEF)-15 score and visual analogue scale (VAS) were assessed at baseline and after 3 months. Results: Two-hundred forty-four patients were enrolled. Of these, 125 received intralesional HA (Group A), 119 received intralesional verapamil (Group B). At enrollment, median age was 56.0 years (interquartile range [IQR]=47.0–63.0 years), median curvature 35.0° (IQR=25.0°–45.0°), median IIEF-15 score 19.0 (IQR=16.0–23.0), median VAS 4.0 (IQR=4.0–5.0). Median difference for IIEF-15 was 1.0 (95% confidence interval [CI]=1.12–1.94) in Group A and 0.0 (95% CI=-0.04–0.14) in Group B (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|